Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies

Zishuo I. Hu, Azam Ghafoor, Manjistha Sengupta, Raffit Hassan

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for the management of malignant mesothelioma.

Original languageEnglish
Pages (from-to)1010-1020
Number of pages11
Issue number7
StatePublished - Apr 1 2021


  • chimeric antigen receptor T cells (CAR T cells)
  • cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitor
  • immunotherapy
  • mesothelin
  • mesothelioma
  • programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor


Dive into the research topics of 'Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies'. Together they form a unique fingerprint.

Cite this